Kunimoto Hiroyoshi, Sakuma Takayuki, Ohashi Takuma, Shirafuta Mayoko, Teranaka Hiroshi, Nakajima Hideaki
Department of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
EJHaem. 2024 Nov 25;5(6):1335-1339. doi: 10.1002/jha2.1057. eCollection 2024 Dec.
Anemia is a major clinical manifestation seen in myelodysplastic syndromes (MDS). Treatment options for anemia in low-risk MDS are limited. Especially, oral medication which is uniformly effective for anemia in low-risk MDS is required. Hypoxia-inducible factor (HIF) prolyl hydroxylase (HIF-PH) inhibitors, such as daprodustat, are oral tablets effective for renal anemia. Pharmacological restoration of HIF activity by HIF-PH inhibitors may be beneficial for MDS-related anemia as well. Yet, their efficacy and safety against low-risk MDS are unclear. Here, we report two cases of low-risk MDS complicated with chronic kidney disease whose anemia responded to daprodustat treatment.
贫血是骨髓增生异常综合征（MDS）的主要临床表现。低危MDS贫血的治疗选择有限。特别是，需要一种对低危MDS贫血普遍有效的口服药物。缺氧诱导因子（HIF）脯氨酰羟化酶（HIF-PH）抑制剂，如达普司他，是治疗肾性贫血有效的口服片剂。HIF-PH抑制剂对HIF活性的药理恢复可能对MDS相关贫血也有益。然而，它们对低危MDS的疗效和安全性尚不清楚。在此，我们报告两例合并慢性肾脏病的低危MDS患者，其贫血对达普司他治疗有反应。
